Pembrolizumab plus axitinib continued to demonstrate superior efficacy compared with sunitinib monotherapy in patients with previously untreated advanced clear-cell RCC with a median follow-up of 42 months.
With approximately 5 years of follow-up, KEYNOTE-052 reports continued durable antitumor activity with pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced/metastatic urothelial cancer, especially those with PD-L1 CPS ≥10.
With a median follow-up of 5 years, pembrolizumab continued to show improved overall survival compared with investigator’s choice of chemotherapy in patients with recurrent advanced urothelial cancer on the KEYNOTE-045 trial.
Exploratory analyses of the CheckMate 9ER trial suggested PFS benefit with nivolumab + cabozantinib vs sunitinib across assessed subgroups defined by baseline disease characteristics.
In patients with metastatic castration-sensitive prostate cancer, the addition of abiraterone to standard of care, ADT with or without docetaxel, prolonged median radiographic PFS by more than 2 years.
Updated safety analysis of EORTC GUCG 1333/PEACE-3 confirms that risk of fractures was well controlled in both treatment arms when patients with mCRPC received BPAs.
In this phase III trial, addition of 177Lu-PSMA-617 to standard of care in men with previously treated PSMA-positive mCRPC prolonged OS and radiographic PFS vs standard of care alone.
Results of the first interim analysis for this randomized, double-blind phase III trial demonstrated significantly improved DFS with adjuvant pembrolizumab in patients with clear-cell RCC following nephrectomy.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.